A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

  1. Zhanwei Du
  2. Lin Wang
  3. Yuan Bai
  4. Yunhu Liu
  5. Eric HY Lau
  6. Alison P Galvani
  7. Robert M Krug
  8. Benjamin John Cowling  Is a corresponding author
  9. Lauren A Meyers  Is a corresponding author
  1. University of Hong Kong, Hong Kong
  2. University of Cambridge, United Kingdom
  3. Yale University, United States
  4. The University of Texas at Austin, United States
  5. University of Hong Kong, China

Abstract

Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0%-16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.

Data availability

All data used in this study can be accessed through Github: https://github.com/ZhanweiDU/PaxHK/.

Article and author information

Author details

  1. Zhanwei Du

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2020-767X
  2. Lin Wang

    Department of Genetics, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5371-2138
  3. Yuan Bai

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
  4. Yunhu Liu

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
  5. Eric HY Lau

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
  6. Alison P Galvani

    Center for Infectious Disease Modeling and Analysis, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  7. Robert M Krug

    Department of Molecular Biosciences, The University of Texas at Austin, Austin, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3754-5034
  8. Benjamin John Cowling

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
    For correspondence
    bcowling@hku.hk
    Competing interests
    Benjamin John Cowling, reports honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer,Sanofi Pasteur, and Roche. The authors report no other potential conflicts of interest.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6297-7154
  9. Lauren A Meyers

    Department of Integrative Biology, The University of Texas at Austin, Austin, United States
    For correspondence
    laurenmeyers@austin.utexas.edu
    Competing interests
    No competing interests declared.

Funding

Innovation and Technology Commission (AIR@InnoHK)

  • Zhanwei Du

Health and Medical Research Fund (07210147)

  • Zhanwei Du

National Natural Science Foundation of China (82304204)

  • Yuan Bai

National Institutes of Health (AI151176)

  • Lauren A Meyers

Centers for Disease Control and Prevention (U01IP001136)

  • Lauren A Meyers

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Individual patient-informed consent was not required in this study using anonymized data.

Copyright

© 2024, Du et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,563
    views
  • 213
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zhanwei Du
  2. Lin Wang
  3. Yuan Bai
  4. Yunhu Liu
  5. Eric HY Lau
  6. Alison P Galvani
  7. Robert M Krug
  8. Benjamin John Cowling
  9. Lauren A Meyers
(2024)
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
eLife 13:e89801.
https://doi.org/10.7554/eLife.89801

Share this article

https://doi.org/10.7554/eLife.89801

Further reading

    1. Epidemiology and Global Health
    Xiaoning Wang, Jinxiang Zhao ... Dong Liu
    Research Article

    Artificially sweetened beverages containing noncaloric monosaccharides were suggested as healthier alternatives to sugar-sweetened beverages. Nevertheless, the potential detrimental effects of these noncaloric monosaccharides on blood vessel function remain inadequately understood. We have established a zebrafish model that exhibits significant excessive angiogenesis induced by high glucose, resembling the hyperangiogenic characteristics observed in proliferative diabetic retinopathy (PDR). Utilizing this model, we observed that glucose and noncaloric monosaccharides could induce excessive formation of blood vessels, especially intersegmental vessels (ISVs). The excessively branched vessels were observed to be formed by ectopic activation of quiescent endothelial cells (ECs) into tip cells. Single-cell transcriptomic sequencing analysis of the ECs in the embryos exposed to high glucose revealed an augmented ratio of capillary ECs, proliferating ECs, and a series of upregulated proangiogenic genes. Further analysis and experiments validated that reduced foxo1a mediated the excessive angiogenesis induced by monosaccharides via upregulating the expression of marcksl1a. This study has provided new evidence showing the negative effects of noncaloric monosaccharides on the vascular system and the underlying mechanisms.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Amanda C Perofsky, John Huddleston ... Cécile Viboud
    Research Article

    Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the contribution of this process to variability in annual epidemics is not well understood. Here, we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the United States during 1997—2019. We integrate phenotypic measures of HA antigenic drift and sequence-based measures of HA and NA fitness to infer antigenic and genetic distances between viruses circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology. Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics, higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults relative to children, consistent with increased population susceptibility. Based on random forest models, A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that subtype interference is a major driver of influenza A virus infection ynamics, presumably via heterosubtypic cross-immunity.